INTERPACE BIOSCIENCES, INC. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data INTERPACE BIOSCIENCES, INC. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	13.1	15.9	21.9	24.2	32.4	33.1	31.8	40	46.9	38.7
Cost of revenue	6.64	7.36	10.2	15.9	21.7	14.3	13.6	15	17	14.6
Gross profit	6.44	8.54	11.7	8.33	10.7	18.8	18.2	25.1	29.9	24.1
Research and development	1.65	1.46	2.12	2.81	2.8	1.49	0.7	0.64	0.68	0.64
Selling and marketing	5.46	6.57	8.42	11.1	9.25	9.18	9.13	10.2	11.7	9.92
General and administrative	10.5	9.15	8.68	14.4	18.2	10.7	11	9.36	9.49	9.48
Operating expenses	12.9	14.8	24.3	34.8	36.8	25.1	21.8	21.1	21.8	20
Operating income	-6.44	-6.29	-12.6	-26.4	-26.1	-6.34	-3.62	3.96	8.11	4.08
Interest expense	2.14	0.43	0.33	0.44	0.55
Other non-operating income	0.01	-2.13	0.26	0.2	0.47	-0.37	-1.21	-0.67
Pre-tax income	-8.57	-13.1	-12.7	-26.7	-26.1	-7.74	-5.84	2.28	6.95	3.77
Income tax	-0.16	-0.4	0.02	-0.03	0.05	-0.71	0.03	0.02	0	-21.2
Income from continuing operations	-8.41	-12.7	-12.7	-26.7	-26.2	-14.7				4.1
Net income	-22	12.6	-12.7	-26.7	-26.5	-14.9	-22	1.95	6.7	24.6
EBITDA	-1.96	-2.6	-8.83	-21.9	-20.6	-0.96	-1.06	4.98	8.41	4.51
EPS, basic	-302.25	-19.90	-11.30	-18.13	-18.30	-9.03	-12.95	0.45	1.42	5.55
EPS, diluted	-302.25	-19.90	-11.30	-18.13	-18.30	-9.03	-12.95	0.45	0.40	0.89
Shares, basic (weighted)	0.73	6.31	1.13	1.5	1.61	1.65	1.7	4.32	4.39	4.42
Shares, diluted (weighted)	0.73	6.31	1.13	1.5	1.61	1.65	1.7	4.36	15.7	27.7

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	0.6	15.2	6.07	2.32	2.77	2.67	4.83	3.5	1.46	2.51
Receivables	2.21	3.44	9.48	10.3	8.03	4.67	5.03	5.08	8.54	5.65
Inventory				1.83	2.05	0.83	1.22	1.23	1.21	1.11
Other current assets	1.42	1.17	2.17	3.85	2.72	1.48	2.29	1.84	1.77	1.75
Total current assets	4.24	19.8	17.7	16.5	14.1	12.2	12.2	10.4	11.8	9.9
Property, plant and equipment	0.93	0.65	0.84	6.81	7.35	0.32	0.48	0.79	1.36	1.42
Lease right-of-use assets				3.89	4.38	1.28	2.44	1.86	1.61	1.22
Goodwill				8.43	8.43	8.43
Intangible assets	36.4	33.1	12.5	15.8	11.4	2.13	0.86
Other non-current assets	0.25	0.03	0.03	0.04	0.04	0.14	0.05	0.05	0.05	0.04
Total assets	25.1	36.6	31.1	51.5	45.7	38.4	16	13.1	14.8	33.8
Accounts payable	2.33	0.39	1.06	4.71	4.51	1.37	1.05	1.54	1.66	0.98
Accrued liabilities	6.24	1.39	1.54	0.2	3.16	2.69	1.46	1.97	2.21	1.89
Deferred revenue				0.46	0.05	0.04
Short-term debt				1.51	1.2	0.76	0.58
Total current liabilities	16.2	8.09	8.67	17.3	18.2	15.7	14.3	11.4	10.6	5.1
Long-term debt	7.91			2.71	3.68	0.52	1.85	4.24
Lease liabilities				2.59	3.54	0.52	1.85	1.47	1.18	0.75
Other non-current liabilities		0.08	4.32	4.57	4.64	4.58	4.7	4.97	5.21	5.62
Total liabilities	35.2	13.7	15.7	29.8	28.2	34.3	32.5	22.1	17	11.5
Total debt	7.91			4.22	4.88	1.28	2.43
Paid-in capital	128	173	176	183	184	186	188	188	235	235
Retained earnings	-120	-132	-159	-186	-212	-227	-249	-242	-235	-211
Treasury stock	-1.64	-1.67	-1.68	-1.72	-1.77	-1.87	-1.98	-2.01	-2.05	-2.07
Shareholders' equity	-10.1	22.9	15.4	-4.48	-29.1	-42.4	-58.1	-55.5	-2.22	22.4
Total equity	6.53	22.9	15.4	-4.48	-29.1	-42.4	-58.1	-55.5	-2.22	22.4
Total liabilities and equity	41.8	53.6	31.1	51.5	45.7	38.4	16	13.1	14.8	33.8
Shares outstanding	0.87	11.1	1.15	1.57	1.62	1.68	1.72	4.35	4.41	4.43

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-22	12.6	-12.7	-26.7	-26.5	-14.9	-22	1.95	6.7	24.6
Depreciation and amortization	4.48	3.69	3.8	4.52	5.5	5.37	2.56	1.03	0.3	0.43
Stock-based compensation	0.13	1.06	2.27	1.54	2.19	1.26	1.26	0.63	0.29	0.04
Deferred income tax				0.02	0.04	0.04				-21.3
Change in receivables	4.77	-1.23	-3.55	-1.1	1.73	2.15	-0.13	0.23	-3.47	2.9
Change in payables	0.14	-2.63	0.67	-0.94	-0.2	-1.82	-0.74	0.49	0.12	-0.81
Cash from operations	-7.61	-15.3	-8.67	-19	-14	-8.72	-7.69	3.79	4.65	5.83
Capital expenditures		-0.03	-0.45	-0.13	-1.58	-0.35	-0.32	-0.47	-0.88	-0.36
Acquisitions				-13.8
Cash from investing		-0.03	-0.45	-13.9	-1.58	-0.32	6.21	-0.09	-0.88	-0.36
Debt issued		11.4
Debt repaid	-1.33
Stock issued	1.71	23.1		6.48	0.43	0.34	0.11
Cash from financing	-0.1	29.9	-0.01	29.2	16.6	8.98	3	-5.03	-5.81	-4.43
Net change in cash	-7.71	14.6	-9.13	-3.75	1.05	-0.06	1.51	-1.33	-2.04	1.04
Free cash flow		-15.3	-9.12	-19.1	-15.6	-9.07	-8.01	3.32	3.77	5.48
Interest paid				0.17	0.06	0.42	0.97	1.09	0.63	0.17
Income taxes paid	0.07	0.42	0.32	0.23	0.22	0.37	0.25	0.27	0.01	0.1

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $6.41 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	63.7%	Gross profit / revenue.
Operating margin	11.5%	Operating income / revenue.
EBITDA margin	12.8%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	11.1%	Pre-tax income / revenue.
Net margin	67.6%	Net income / revenue.
FCF margin	11.4%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	12.3%	Cash from operations / revenue.
Effective tax rate	-521.8%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	105.2%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	70.8%	Net income / average total assets.
Return on invested capital (ROIC)	16.0%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	1.6%	Research and development expense / revenue.
Stock-based pay / revenue	0.1%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	1.0%	Capital expenditures / revenue.
D&A / revenue	1.3%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-17.5%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	6.7%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	3.6%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-19.4%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	9.8%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	17.6%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating income growth, 1y	-49.6%	Operating income vs the same period a year earlier. Only from a positive base.
EBITDA growth, 1y	-46.4%	EBITDA vs the same period a year earlier. Only from a positive base.
Net income growth, 1y	266.7%	Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y	122.5%	EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y	25.5%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y	45.2%	Free cash flow vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y	128.8%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	28.4%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	-5.8%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	76.0%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	153.7%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	76.6%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	2.22x	Current assets / current liabilities.
Quick ratio	1.82x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	0.54x	(Cash + short-term investments) / current liabilities.
Liabilities / assets	32.7%	Total liabilities / total assets.
Working capital	$6.0M	Current assets - current liabilities.
Tangible book value	$23.2M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	1.05x	Revenue / average total assets.
Fixed asset turnover	22.3x	Revenue / average property, plant and equipment.
Inventory turnover	12.1x	Cost of revenue / average inventory.
Days inventory	30 days	365 x average inventory / cost of revenue.
Receivables turnover	5.73x	Revenue / average receivables.
Days sales outstanding	64 days	365 x average receivables / revenue.
Days payables	43 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	51 days	Days inventory + days sales outstanding - days payables.
FCF conversion	16.8%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	7.9%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$0.88	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$1.30	Revenue / diluted weighted shares.
FCF per share	$0.15	Free cash flow / diluted weighted shares.
Operating cash flow per share	$0.16	Cash from operations / diluted weighted shares.
Book value per share	$0.84	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	$0.84	Tangible book value / shares outstanding.
Cash per share	$0.10	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$177.6M	Share price x shares outstanding.
Enterprise value	$174.9M	Market cap + total debt - cash - short-term investments.
P/E	7.26x	Market cap / net income. Only when net income is positive.
P/S	4.91x	Market cap / revenue.
P/B	7.64x	Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book	7.64x	Market cap / tangible book value, when positive.
P/FCF	43.3x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	39.8x	Market cap / cash from operations, when positive.
EV/Sales	4.84x	Enterprise value / revenue.
EV/EBIT	42.0x	Enterprise value / operating income, when both are positive.
EV/EBITDA	37.7x	Enterprise value / EBITDA, when both are positive.
EV/FCF	42.6x	Enterprise value / free cash flow, when both are positive.
FCF yield	2.3%	Free cash flow / market cap.
Earnings yield	13.8%	Net income / market cap (the inverse of P/E).

What was INTERPACE BIOSCIENCES, INC.'s revenue in fiscal 2025?

INTERPACE BIOSCIENCES, INC. reported revenue of $38.7M for fiscal 2025, 17.5% lower than the year before.

Was INTERPACE BIOSCIENCES, INC. profitable in fiscal 2025?

Yes. Net income was $24.6M, a net margin of 63.5%.

How much free cash flow did INTERPACE BIOSCIENCES, INC. generate in fiscal 2025?

Cash from operations of $5.8M minus capital expenditures of $356.0K left free cash flow of $5.5M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to INTERPACE BIOSCIENCES, INC.